Theravance Biopharma Set for Investor Engagement at BioConnect
Theravance Biopharma, Inc. (NASDAQ: TBPH) is gearing up for an important opportunity to connect with investors at the H.C. Wainwright 3rd Annual BioConnect Investor Conference. This event promises to be a pivotal moment for the company as it shares valuable insights about its ongoing projects and developments.
Fireside Chat Details
At the conference, Theravance Biopharma will participate in a Fireside Chat. This session is designed to provide an intimate setting for discussing the company’s strategic direction, recent advancements, and future goals. The chat will take place at NASDAQ on a designated day during the conference, making it easy for interested parties to tune in.
Webcast Availability
For those who cannot attend in person, a webcast of the Fireside Chat will be made available. Interested attendees can find the webcast on the company's official website under the Investors section. A recording will be archived for 30 days, ensuring that all stakeholders can catch up on the discussions that take place.
Focus on Innovative Therapeutics
Theravance Biopharma is dedicated to its mission of delivering Medicines that Make a Difference. The company’s innovative spirit drives the development of products like YUPELRI (revefenacin) inhalation solution, which has received FDA approval for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This commitment to innovation underlines Theravance’s position in the biopharma landscape.
Late-Stage Investigational Studies
The company is also advancing Ampreloxetine, a once-daily norepinephrine reuptake inhibitor. This therapy targets symptomatic neurogenic orthostatic hypotension (nOH) in patients suffering from Multiple System Atrophy (MSA). The potential to be a first-in-class treatment underscores Theravance's role in addressing critical health issues and creating meaningful shareholder value.
Commitment to Shareholder Value
Theravance Biopharma remains firmly committed to maximizing shareholder value through strategic investments and innovation in drug development. The company’s efforts are aimed not only at improving patient outcomes but also at ensuring that investors see significant returns on their investments.
About Theravance Biopharma
Theravance Biopharma, Inc. leverages decades of expertise to create transformative therapeutics. By focusing on innovative solutions, they aim to significantly impact the lives of patients. Their dedication to creating effective medications strictly aligns with their purpose of making a difference in healthcare.
Contact Information
For further inquiries, interested parties can reach out directly to Theravance Biopharma. The company emphasizes open communication with its stakeholders, reinforcing its transparent approach to business.
Frequently Asked Questions
What is the focus of Theravance Biopharma?
Theravance Biopharma focuses on developing innovative medications that enhance the quality of life for patients.
When will the Fireside Chat occur?
The exact date and time of the Fireside Chat will be provided during the BioConnect Investor Conference.
How can I access the webcast?
The webcast can be accessed through Theravance Biopharma's website under the Investors section.
What are some of Theravance's key products?
Key products include YUPELRI, an inhalation solution for COPD treatment, and Ampreloxetine, targeting neurogenic orthostatic hypotension.
How does Theravance create shareholder value?
Through innovative drug development and strategic investments, Theravance aims to enhance both patient care and shareholder returns.
